TransCode Therapeutics (RNAZ) Stock Overview

A clinical-stage company, develops immuno-oncology and RNA therapeutics for the treatment of high risk and advanced cancers. More details

RNAZ fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Risk Analysis

Does not have a meaningful market cap ($6M)

Earnings have declined by 32% per year over past 5 years

Makes less than USD$1m in revenue ($0)

RNAZ Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

TransCode Therapeutics, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for TransCode Therapeutics
Historical stock prices
Current Share Price	US$6.60
52 Week High	US$20.99
52 Week Low	US$6.08
Beta	1.4
1 Month Change	-25.00%
3 Month Change	-23.79%
1 Year Change	-1.49%
3 Year Change	-99.90%
5 Year Change	n/a
Change since IPO	-99.90%

Recent updates

Seeking Alpha • Aug 15

TransCode Therapeutics reports Q2 results

TransCode Therapeutics press release (NASDAQ:RNAZ): Q2 Operating loss of $4.7M. TransCode expects that its cash of $13.4 million as of June 30, 2022, is sufficient to fund planned operations into the first quarter 2023 but not for a full 12 months from the date of its financial statements.

Seeking Alpha • Jul 11

TransCode files U.S. patent application for radiotherapy based cancer treatment

TransCode Therapeutics (NASDAQ:RNAZ) on Monday said it had filed a provisional U.S. patent application directed at using radiotherapy through nanoparticles to treat cancer. The U.S. patent application is 63/356,449 and is titled "Radiolabeled Nanoparticles and Template Directed Immunomodulation for Cancer Therapy." RNAZ said the application is directed at introducing radiotherapy into the delivery of nanoparticles carrying RNA-based agonist precursors of pattern recognition receptors. RNAZ stock +3.7% to $1.39 in aftermarket trading.

Analysis Article • Apr 01

We're Hopeful That TransCode Therapeutics (NASDAQ:RNAZ) Will Use Its Cash Wisely

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Analysis Article • Dec 15

Here's Why We're Not Too Worried About TransCode Therapeutics' (NASDAQ:RNAZ) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...

Shareholder Returns

	RNAZ	US Biotechs	US Market
7D	-5.7%	-1.8%	-0.3%
1Y	-1.5%	32.7%	24.1%

Return vs Industry: RNAZ underperformed the US Biotechs industry which returned 32.7% over the past year.

Return vs Market: RNAZ underperformed the US Market which returned 24.1% over the past year.

Price Volatility

Is RNAZ's price volatile compared to industry and market?
RNAZ volatility
RNAZ Average Weekly Movement	7.5%
Biotechs Industry Average Movement	10.9%
Market Average Movement	7.2%
10% most volatile stocks in US Market	16.2%
10% least volatile stocks in US Market	3.2%

Stable Share Price: RNAZ has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: RNAZ's weekly volatility has decreased from 13% to 8% over the past year.

About the Company

Founded	Employees	CEO	Website
2016	12	Philippe Calais	www.transcodetherapeutics.com

TransCode Therapeutics, Inc., a clinical-stage company, develops immuno-oncology and RNA therapeutics for the treatment of high risk and advanced cancers. The company’s therapeutic candidate comprises SEVIPROTIMUT-L for the adjuvant treatment of patients with Stages IIB and IIC melanoma that has completed Phase 2 clinical trial; TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in various cancers comprising breast, pancreatic, ovarian, colon cancer, glioblastomas, and others that has completed Phase 1 clinical trial. Its preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1 and two indication agnostic programs; TTX-RIGA, an RNA- based agonist of the retinoic acid-inducible gene I targeting activation of innate immunity in the tumor microenvironment; and TTX-siMYC, an siRNA-based MYC inhibitor.

TransCode Therapeutics, Inc. Fundamentals Summary

How do TransCode Therapeutics's earnings and revenue compare to its market cap?
RNAZ fundamental statistics
Market cap	US$6.27m
Earnings (TTM)	-US$43.70m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-0.1x

P/E Ratio

Is RNAZ overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
RNAZ income statement (TTM)
Revenue	US$0
Cost of Revenue	US$0
Gross Profit	US$0
Other Expenses	US$43.70m
Earnings	-US$43.70m

Last Reported Earnings

Mar 31, 2026

Next Earnings Date

n/a

Earnings per share (EPS)	-45.98
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0%

How did RNAZ perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/05/18 17:35
End of Day Share Price	2026/05/15 00:00
Earnings	2026/03/31
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

TransCode Therapeutics, Inc. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Emily Bodnar	H.C. Wainwright & Co.

TransCode Therapeutics (RNAZ) Stock Overview

Risk Analysis

TransCode Therapeutics, Inc. Competitors

CollPlant Biotechnologies

Silo Pharma

Alaunos Therapeutics

Aptorum Group

Price History & Performance

Recent News & Updates

TransCode Therapeutics, Inc. Appoints Anna Moore as Chair of Scientific Advisory Board

TransCode Therapeutics, Inc. announced that it expects to receive $19.7 million in funding from Yorkville Advisors Global LP

TransCode Therapeutics, Inc. announced delayed annual 10-K filing

TransCode Therapeutics, Inc. Announces Publication of Preclinical Testing of RIG-I Immunotherapeutic Candidate Supporting Further Development

TransCode Therapeutics, Inc. and Quantum Leap Healthcare Collaborative Announce Submission of Ind Amendment for Phase 2A Clinical Trial Withttx-Mc138

TransCode Therapeutics, Inc. Announces Publication of Preclinical Data Supporting Therapeutic Potential of TTX-MC138 in Glioblastoma

Recent updates

TransCode Therapeutics, Inc. Appoints Anna Moore as Chair of Scientific Advisory Board

TransCode Therapeutics, Inc. announced that it expects to receive $19.7 million in funding from Yorkville Advisors Global LP

TransCode Therapeutics, Inc. announced delayed annual 10-K filing

TransCode Therapeutics, Inc. Announces Publication of Preclinical Testing of RIG-I Immunotherapeutic Candidate Supporting Further Development

TransCode Therapeutics, Inc. and Quantum Leap Healthcare Collaborative Announce Submission of Ind Amendment for Phase 2A Clinical Trial Withttx-Mc138

TransCode Therapeutics, Inc. Announces Publication of Preclinical Data Supporting Therapeutic Potential of TTX-MC138 in Glioblastoma

TransCode Therapeutics Presents Preliminary Data from Its Completed Phase 1a Study with Tx-MC138 in Metastatic Disease at ESMO

TransCode Therapeutics, Inc. announced that it expects to receive $25.00146 million in funding

TransCode Therapeutics, Inc., Annual General Meeting, Aug 29, 2025

TransCode Therapeutics, Inc. Successfully Completes Initial Dosing of Patients in Cohort 4 of Phase 1a Clinical Trial

TransCode Therapeutics, Inc. Reports Further Progress on Phase 1A Clinical Trial with No Dose Limiting Toxicities Reported in Patients with Metastatic Cancer

TransCode Therapeutics, Inc. announced delayed annual 10-K filing

TransCode Therapeutics, Inc. Announces Initial Dosing in Fourth Cohort of Phase 1 Clinical Trial Withttx-Mc138

TransCode Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $10.045 million.

TransCode Therapeutics, Inc. has filed a Follow-on Equity Offering.

TransCode Therapeutics, Inc. Announces Safety Review Committee Approval to Open Fourth Cohort in Phase I/II Clinical Trial

TransCode Therapeutics, Inc. Announces Completion of Cohort 3 Initial Dosing with Lead Candidate in Phase 1 Clinical Trial

TransCode Therapeutics Announces First Patient Dosed in Third Cohort with Lead Candidate in Phase 1 Clinical Trial

Transcode Therapeutics, Inc. Announces Safety Review Committee Approval of Opening Third Cohort and Preliminary Results from First Cohort in Phase 1TTX-MC138 Clinical Trial

TransCode Therapeutics Announces Effective Date for 1-for-33 Reverse Stock Split to Meet the Minimum Bid Price Requirement

TransCode Therapeutics, Inc. announced that it expects to receive $8 million in funding

TransCode Therapeutics Announces 1-for-33 Reverse Stock Split to Regain Compliance with Nasdaq Bid Price Requirement

TransCode Therapeutics Announces Nasdaq Extension to Regain Compliance

Transcode Therapeutics, Inc. Announces Safety Review Committee Approval of Second Cohort Opening in Phase 1Ttx-Mc138 Clinical Trial Following Favorable Review of Cohort 1 Safety Data

Transcode Therapeutics Completes Initial Dosing of First Cohort in Phase 1 Clinical Trial with TTX-MC138, A MicroRNA-Targeted Technology

TransCode Therapeutics, Inc. Receives Non-Compliance Letter from Staff of Nasdaq

TransCode Therapeutics, Inc. Announces First Patients Treated in Phase 1 Clinical Trial with First-In-Class Lead Therapeutic Candidate

TransCode Therapeutics Receives Deficiency Letters from the Listing Qualifications Department (The “Staff”) of the Nasdaq

TransCode Therapeutics, Inc. Announces Phase 1 Clinical Trial Initiation

TransCode Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $3 million.

TransCode Therapeutics, Inc. has filed a Follow-on Equity Offering.

TransCode Therapeutics, Inc. Reports Positive Data from First-In-Human Clinical Study Using Novel Lead Therapeutic Candidate, TTX-MC138

TransCode Therapeutics Intends to File a Request for a Hearing on or before May 14, 2024, in Response to Non-Compliance with the Nasdaq Listing Rule 5550(a)(2)

TransCode Therapeutics, Inc., Annual General Meeting, Jun 13, 2024

TransCode Therapeutics, Inc. Announces Fda Clearance to Initiate Phase 1/2 Clinical Trial Withttx-Mc138 in Patients with Advanced Solid Tumors

TransCode Therapeutics, Inc. Announces Appointment of Daniel Vlock, M.D., as Chief Medical Officer

TransCode Therapeutics Reports Publication of United States Patent Application Covering TransCode’s RIG-I Agonist Immunotherapeutic

TransCode Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $7.194863 million.

TransCode Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $7.25 million.

TransCode Therapeutics, Inc. Announces CEO Changes

TransCode Therapeutics, Inc. Announces Management Changes

TransCode Therapeutics, Inc. has filed a Follow-on Equity Offering.

TransCode Therapeutics, Inc. Reports Positive Pre-Clinical Results in Metastatic Pancreatic Cancer with Its Lead Candidate, TTX-MC138

TransCode Therapeutics, Inc. to Present Phase 0 Data at 2023 San Antonio Breast Cancer Symposium

TransCode Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $1.21 million.

TransCode Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $1.21 million.

TransCode Therapeutics Receives Letter from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement Required for Continued Listing on The Nasdaq Capital Market

Nasdaq Panel Grants TransCode Therapeutics Extension for Continued Listing on the Nasdaq Stock Market Subject to Conditions

Transcode Therapeutics, Inc. Announces Preliminary Clinical Results in First Patient in Phase 0 Clinical Study with Leading Therapeutic Candidate, Tx-Mc138

TransCode Therapeutics, Inc. Announces Positive Pre-Clinical Glioblastoma Results with Lead Therapeutic Candidate,TTX-MC138

TransCode Therapeutics, Inc. Announces First Subject Dosed with Radiolabeled TTX-MC138 in First-In-Human Clinical Trial

TransCode Therapeutics Provides Non Compliance Update

TransCode Therapeutics Receives Delisting Determination Letter from Nasdaq Advising Not to Accept its Compliance Plan, and Denies its Request for an Extension

TransCode Therapeutics, Inc. Announces Publication of New Data Supporting Use of TTX-MC138 for Treatment of Metastatic Breast Cancer

New major risk - Shareholder dilution

TransCode Therapeutics, Inc. Reports Positive Preclinical Results with its Lead Candidate, Tx-MC138, in Glioblastoma

TransCode Therapeutics Announces 1-For-20 Reverse Stock Split to Satisfy the Minimum Bid Price Requirement for Continued Listing on the Nasdaq Capital Market

TransCode Therapeutics Receives Deficiency Letter from Nasdaq Regarding Non-Compliance with the Minimum Stockholders’ Equity Requirement

TransCode Therapeutics, Inc. Reports Positive Preclinical Results with its Immunotherapy Candidate, TTX-RIGA, in Melanoma

Transcode Therapeutics, Inc. Announces FDA Authorization to Proceed with First-In-Human Clinical Trial

Transcode Therapeutics Announces Eind Submission to Us Fda for Planned First-In-Human Clinical Trial in Patients with Advanced Solid Tumors

TransCode Therapeutics Reports Positive Preclinical Results with its Immunotherapy Candidate, TTX-siPDL1, in Pancreatic Adenocarcinoma

TransCode Therapeutics, Inc. Reports Positive Preclinical Results with Its Lead Candidate, TTX-MC138

TransCode Therapeutics Announces Publication of Feline Case Study in Frontiers in Oncology